Cancer clinical trials are notorious for their staggering operational burdens—dense protocols, exhaustive data fields, and narrow eligibility windows that throttle patient enrollment and drive up costs. A new Phase III trial design in non-small cell lung cancer is challenging that status quo, offering a structural template that could meaningfully accelerate how quickly effective therapies reach patients.
PROSPECT-Lung (CTIU2317-A082304-S2402) is a randomized, open-label, pragmatic Phase III trial comparing perioperative versus adjuvant immunotherapy-based strategies in patients with resectable NSCLC, using real-world event-free survival and overall survival at three years as primary endpoints. What makes it analytically interesting is the infrastructure comparison to an existing Phase III trial in the same disease space—Alliance A081801—which enrolled similar patients under a conventional design. Against that benchmark, PROSPECT-Lung compressed protocol length from 88 to 30 pages, a 65% reduction, while slashing per-patient data collection from 2,523 fields to 438, an 82.6% reduction, achieved by replacing cycle-by-cycle data capture with summary-level documentation.
This matters beyond oncology. Clinical trial inefficiency is a systemic drag on medical progress across all therapeutic areas—cardiovascular, metabolic, neurological. The pragmatic trial framework PROSPECT-Lung employs borrows from epidemiological principles applied to real-world populations: relaxed eligibility criteria that better reflect actual patients, leaner data architectures, and shorter protocol documents that reduce staff training burdens. The principal methodological tension here is whether summary-level data collection preserves sufficient granularity to detect safety signals and protocol deviations. Regulators have historically favored dense data capture precisely because endpoints and adverse event patterns are difficult to reconstruct from sparse records. This trial's outcomes will serve as a natural experiment: if scientific integrity holds at 438 data fields, it challenges the necessity of legacy data requirements industry-wide. The finding is incremental in one sense—pragmatic trial designs are not new—but its application to a live, large-scale Phase III immunotherapy comparison in lung cancer gives it substantive real-world weight.